• news.cision.com/
  • Curasight/
  • Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma)

Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma)

Report this content
  • Preclinical studies show uTREAT® efffective in treating aggressive brain cancer
  • Data supports strategy to move uTREAT® into clinical development for evaluation in patients with aggressive brain cancer

Copenhagen, June 7, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating the effectiveness of uTREAT® in treating aggressive brain cancer (glioblastoma). The results from the study validate Curasight's strategic focus on developing uTREAT® as a viable treatment option for patients with aggressive brain cancer.

Data from the study showed that uTREAT®, when administered to a preclinical model of human aggressive brain cancer, effectively inhibited tumor growth. Animals receiving uTREAT® survived longer compared to animals not treated with uTREAT®. These data demonstrates the potential for uTREAT® to be used as a radioligand therapy for the treatment of aggressive brain cancer and supports further development for this treatment.

"We are extremely encouraged by these results, which further affirm our commitment to advancing our theranostic platform, comprising uTRACE® and uTREAT®, for evaluation in patients with aggressive brain cancer. The urgent need to enhance therapeutic outcomes in this challenging disease drives our strategic pursuit," commented Ulrich Krasilnikoff, CEO of Curasight.

About high grade glioma and glioblastoma

Treatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Curasight's research and development efforts aim to address this challenge and improve the lives of patients facing aggressive brain cancer. Glioblastoma is the first indication for uTREAT®, but uTREAT® has also potential in several other cancer types expressing the biomarker uPAR. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed with the aggressive form, glioblastoma, annually in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive.

This information is such information that Curasight A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the below contact person, for publication on June 7, 2023.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com


Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.